Valentina Goularte
Acute Care · Baltimore, MDNPI 1083208466
Payments from drug & device makers
What this record shows
Johnson & Johnson accounts for 65.1% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $3,029, 5.0 times the $601 reported in 2022. Among acute care clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 18 payments — averaging $238.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- E.r. Squibb & Sons, L.L.C.$365
- Exelixis Inc.$134
- AbbVie$125
- Eisai Inc.$125
- GSK$121
- plus $630 from 7 others
What the payments were for
- Speaking & faculty fees$2,55059%
- Food & beverage$1,74841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $2,799 |
| E.r. Squibb & Sons, L.L.C. | 3 | $365 |
| Exelixis Inc. | 1 | $134 |
| AbbVie | 1 | $125 |
| Eisai Inc. | 1 | $125 |
| GSK | 1 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $120 |
| AstraZeneca | 1 | $118 |
| Astellas Pharma US Inc | 1 | $118 |
| Genentech USA, Inc. | 1 | $118 |
| Gilead | 1 | $106 |
| Pfizer | 1 | $31 |
| Incyte Corporation | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,298 in reported general payments places this provider in the 95th percentile of 502 acute care providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 15 | $229 |
Paid to pharmacies, not to this prescriber.
Other acute care in Baltimore
- Paige GriffithBaltimore$106K
- T Nicole KelleyBaltimore$46K
- Amy GoodrichBaltimore$27K
- Rama AnthonyBaltimore$20K
- Susan HuppmannBaltimore$16K
- Eleanor DunlapBaltimore$11K
- Lateaqua AlstonBaltimore$9K
- Archana PatelBaltimore$8K
- Tamara HillBaltimore$8K
- Robert GoodfellowBaltimore$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.